GlassScriptPhysician profile
Mia Decapua
NPI 1659044303
$3,066.26
in general payments reported to CMS, 2019-2025
14 companies · $175 in 2025
The $175 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $309 · 2022: $480 · 2023: $1,808 · 2024: $295 · 2025: $175.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,205 · Food and Beverage: $1,073.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,204.76 |
| Food and Beverage | $1,073.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,617.87 | 2022-2023 | Air Optix, Dailies Aqua Comfort Plus, Dailies Total1 Multifocal |
| Sun Pharmaceutical Industries INC. | $330.22 | 2021-2025 | Cequa |
| Genzyme Corporation | $212.36 | 2022-2023 | |
| Sight Sciences, INC. | $170.79 | 2021-2023 | Tearcare System |
| Astellas Pharma US INC | $130.74 | 2024 | Izervay |
| Biotissue Holdings INC. | $129.38 | 2022-2025 | |
| Allergan, INC. | $129.24 | 2021 | |
| Apellis Pharmaceuticals, INC. | $113.96 | 2023 | |
| Bausch & Lomb Americas INC. | $93.65 | 2024-2025 | Xiidra, Miebo |
| Abbvie INC. | $67.62 | 2024-2025 | |
| Johnson & Johnson Vision Care, INC. | $20.06 | 2023 | |
| Travere Therapeutics, INC. | $19.10 | 2023 | Cholbam |
| Regeneron Healthcare Solutions, INC. | $16.88 | 2022 | |
| Oyster Point Pharma, INC. | $14.39 | 2023 | Tyrvaya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mia Decapua listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.